News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Peregrine Announces Opening of a New Study At the Stanford University, Stanford, CA (Business Wire)...~~~ Cotara, Peregrine`s Tumor Necrosis Therapy (TNT) drug, is a radiolabeled monoclonal antibody that binds to the necrotic core of tumors and uses beta-radiation to kill the tumors from the inside out.......Cotara is currently being studied in a multi-center Phase II study for Brain cancer....- Apr 09 7:31 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010409/2064.html

Posted on: 04/09/2001

"Yahoo - Peregrine Announces Opening of a New Study At the Stanford University, Stanford, CA"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
PPHM
1.25
+0.0625
delayed 20 mins - disclaimer
Monday April 9, 7:31 am Eastern Time

Press Release

Peregrine Announces Opening of a New Study At the Stanford University, Stanford, CA

New Trial to Explore Use of Cotara in Soft Tissue Sarcoma

TUSTIN, Calif.--(BUSINESS WIRE)--April 9, 2001--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM - news) announced today that a new study entitled " Phase I Evaluation of Intravenous 131I-chTNT-1/B for the Treatment of Advanced Soft Tissue Sarcoma" will evaluate the use of Cotara(TM) in patients with advanced soft tissue sarcoma.

The principal investigator is Dr. Susan Knox, Associate Professor of Radiation Oncology. Patients will receive Cotara(TM) in order to determine the safety and characteristics of the drug in this patient population. "We are pleased to continue our work with Dr. Knox. This study is part of a series to characterize the effects of Cotara(TM) when administered intravenously to patients with advanced cancer," said Dr. Terrence Chew, Peregrine's Vice President of Clinical and Regulatory Affairs.

"We are pleased to expand our Cotara clinical studies at Stanford University", said Edward Legere, Peregrine's President and CEO. "Given the potential broad applications of our Cotara anti-cancer agent, Peregrine intends to continue to expand human clinical studies of this novel anti-cancer technology into numerous cancer types."

Cotara, Peregrine's Tumor Necrosis Therapy (TNT) drug, is a radiolabeled monoclonal antibody that binds to the necrotic core of tumors and uses beta-radiation to kill the tumors from the inside out. Unlike traditional treatments such as chemotherapy, pre-clinical studies have shown TNT grows more effective with successive use as the region of necrosis grows in size. Since necrotic tissue is common to all tumors, TNT may have broad application across all tumor types.

Cotara is currently being studied in a multi-center Phase II study for Brain cancer. Peregrine expects to begin a Phase III study for Brian cancer later this year. Cotara is also in a Phase I study for Colorectal cancer at Stanford University. Peregrine plans to open two additional clinical studies soon, and it plans to open two additional Cotara Phase I studies within the next 12 months.

Peregrine Pharmaceuticals Inc. is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies." These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents, (VTA). The Company also has a direct tumor-targeting agent called Oncolym® for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym® has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym® clinical trial programs as well as marketing.

Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10K for the year ended April 30, 2000 and Form 10Q for the quarter ended January 31, 2001.


Contact:
     DeMonte Associates
     Cynthia DeMonte, 800/987-8256 or 212/420-0088

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Peregrine Pharmaceuticals Inc (NasdaqSC:PPHM - news)
Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740